Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Promyelocytic, Acute 5Thrombocytopenia 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Leukemia 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Primary Myelofibrosis 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligometastatic Disease 1Oligodendroglioma 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hematologic Diseases 1Head and Neck Neoplasms 1HER2 Negative Breast Cancer 1Glioma 1

Interventions

Temozolomide 42Magnetic Resonance Spectroscopy 41Radiotherapy 22Specimen Handling 18Biopsy 13X-Rays 10Radiation 10trametinib 8Bevacizumab 8Nivolumab 7Blood Specimen Collection 7olaparib 6fluorodopa F 18 6dabrafenib 6Radiotherapy, Intensity-Modulated 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Lomustine 6pembrolizumab 5abemaciclib 5Standard of Care 5vorasidenib 4ulixertinib 4larotrectinib 4ivosidenib 4erdafitinib 4Surgical Procedures, Operative 4Dianhydrogalactitol 4Cyclophosphamide 4Aminolevulinic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Tretinoin × 1 year × Clear all
NCT05345002 2026-02-20

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
55 enrolled
CNS

Astrocytoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡